Mindblown: a blog about philosophy.
Meta appeals against EU gatekeeper status for Messenger, Marketplace
By Supantha Mukherjee and Foo Yun Chee STOCKHOLM/BRUSSELS (Reuters) – Meta on Wednesday appealed against “gatekeeper” designations for its Messenger and Marketplace platforms, the first Big Tech company to challenge new European Union rules setting out dos and don’ts for the online services. As part of its latest crackdown on Big Tech, the EU in […]
Meta appeals against EU gatekeeper status for Messenger, Marketplace
By Supantha Mukherjee and Foo Yun Chee STOCKHOLM/BRUSSELS (Reuters) – Meta on Wednesday appealed against “gatekeeper” designations for its Messenger and Marketplace platforms, the first Big Tech company to challenge new European Union rules setting out dos and don’ts for the online services. As part of its latest crackdown on Big Tech, the EU in […]
Meta appeals against EU gatekeeper status for Messenger, Marketplace
By Supantha Mukherjee and Foo Yun Chee STOCKHOLM/BRUSSELS (Reuters) – Meta on Wednesday appealed against “gatekeeper” designations for its Messenger and Marketplace platforms, the first Big Tech company to challenge new European Union rules setting out dos and don’ts for the online services. As part of its latest crackdown on Big Tech, the EU in […]
Meta appeals against EU gatekeeper status for Messenger, Marketplace
By Supantha Mukherjee and Foo Yun Chee STOCKHOLM/BRUSSELS (Reuters) – Meta on Wednesday appealed against “gatekeeper” designations for its Messenger and Marketplace platforms, the first Big Tech company to challenge new European Union rules setting out dos and don’ts for the online services. As part of its latest crackdown on Big Tech, the EU in […]
Investors in thematic funds hurt returns by trading too frequently: Morningstar
By Bansari Mayur Kamdar (Reuters) – Investors in thematic funds cut their returns by nearly two-thirds through badly-timed trades, a report by Morningstar Manager Research showed. Funds that tend to focus on specific themes, such as climate change or artificial intelligence, have drawn investors over the last few years, more than doubling their assets under […]
Investors in thematic funds hurt returns by trading too frequently: Morningstar
By Bansari Mayur Kamdar (Reuters) – Investors in thematic funds cut their returns by nearly two-thirds through badly-timed trades, a report by Morningstar Manager Research showed. Funds that tend to focus on specific themes, such as climate change or artificial intelligence, have drawn investors over the last few years, more than doubling their assets under […]
Investors in thematic funds hurt returns by trading too frequently: Morningstar
By Bansari Mayur Kamdar (Reuters) – Investors in thematic funds cut their returns by nearly two-thirds through badly-timed trades, a report by Morningstar Manager Research showed. Funds that tend to focus on specific themes, such as climate change or artificial intelligence, have drawn investors over the last few years, more than doubling their assets under […]
Investors in thematic funds hurt returns by trading too frequently: Morningstar
By Bansari Mayur Kamdar (Reuters) – Investors in thematic funds cut their returns by nearly two-thirds through badly-timed trades, a report by Morningstar Manager Research showed. Funds that tend to focus on specific themes, such as climate change or artificial intelligence, have drawn investors over the last few years, more than doubling their assets under […]
Awakn Life Sciences gets green light for phase III trial in SAUD treatment
Awakn Life Sciences Corp., a Toronto-based biotech firm, has received critical approvals to advance its pioneering treatment for Severe Alcohol Use Disorder (SAUD). The Medicines and Healthcare products Regulatory Agency (MHRA) and the UK Health Research Authority have sanctioned a phase III clinical trial for AWKN-P001, a drug combining ketamine and psycho-social support. This major […]
Awakn Life Sciences gets green light for phase III trial in SAUD treatment
Awakn Life Sciences Corp., a Toronto-based biotech firm, has received critical approvals to advance its pioneering treatment for Severe Alcohol Use Disorder (SAUD). The Medicines and Healthcare products Regulatory Agency (MHRA) and the UK Health Research Authority have sanctioned a phase III clinical trial for AWKN-P001, a drug combining ketamine and psycho-social support. This major […]
Got any book recommendations?